Elevated soluble Tim-3 correlates with disease activity of systemic lupus erythematosus

References

• Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1(2):147–153.
   PubMed Web of Science ®Google Scholar
• Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138–145.
   PubMed Web of Science ®Google Scholar
• Mak A, Isenberg DA, Lau CS. Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol. 2013;9(5):301–310.
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10(2):93–96.
   PubMed Web of Science ®Google Scholar
• Nived O, Jönsen A, Bengtsson AA, et al. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002;29(7):1398–1400.
   PubMed Web of Science ®Google Scholar
• Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology. 2012;51(3):491–498.
   PubMed Web of Science ®Google Scholar
• Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010;19(8):949–956.
   PubMed Web of Science ®Google Scholar
• Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev. 2014;13(7):770–777.
   PubMed Web of Science ®Google Scholar
• Mok CC. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol. 2010;2010:638413.
   PubMedGoogle Scholar
• Zhang H, Huang X, Ye L, et al. B cell-related circulating microRNAs with the potential value of biomarkers in the differential diagnosis, and distinguishment between the disease activity and lupus nephritis for systemic lupus erythematosus. Front Immunol. 2018;29(9):1473.
   Google Scholar
• Guo G, Ye S, Xie S, et al. The cytomegalovirus protein US31 induces inflammation through mono-macrophages in systemic lupus erythematosus by promoting NF-κB2 activation. Cell Death Dis. 2018;9(2):104.
   PubMedGoogle Scholar
• Herbst R, Liu Z, Jallal B, et al. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis. 2012;15(5):433–446.
   PubMed Web of Science ®Google Scholar
• Ahearn JM, Liu CC, Kao AH, et al. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159(4):326–342.
   PubMed Web of Science ®Google Scholar
• Živković V, Cvetković T, Mitić B, et al. Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study. Rheumatol Int. 2018;38(6):1003–1008.
   PubMed Web of Science ®Google Scholar
• Kamala PS, Thirumagal T, Ivan M, et al. FLI1 levels impact CXCR3 expression and renal infiltration of T cells and renal glycosphingolipid metabolism in the MRL/lpr lupus mouse strain. J Immunol. 2015;195(12):5551–5560.
   PubMed Web of Science ®Google Scholar
• Liao J, Liu Y, Wu H, et al. The role of icaritin in regulating Foxp3/IL17a balance in systemic lupus erythematosus and its effects on the treatment of MRL/lpr mice. Clin Immunol. 2016;162:74–83.
   PubMed Web of Science ®Google Scholar
• Munoz LE, Gaipl US, Franz S, et al. SLE-a disease of clearance deficiency? Rheumatology. 2005;44(9):1101–1107.
   PubMed Web of Science ®Google Scholar
• Schulze C, Munoz LE, Franz S, et al. Clearance deficiency-a potential link between infections and autoimmunity. Autoimmun Rev. 2008;8(1):5–8.
   PubMed Web of Science ®Google Scholar
• Koguchi K, Anderson DE, Yang L, et al. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203(6):1413–1418.
   PubMed Web of Science ®Google Scholar
• Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127(1):78–88.
   PubMed Web of Science ®Google Scholar
• Wang Y, Meng J, Wang X, et al. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol. 2008;67(1):63–70.
   PubMed Web of Science ®Google Scholar
• Niwa H, Satoh T, Matsushima Y, et al. Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Clin Immunol. 2009;132(2):184–194.
   PubMed Web of Science ®Google Scholar
• Song LJ, Wang X, Wang XP, et al. Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus. Diagn Pathol. 2015;10(1):71.
   PubMedGoogle Scholar
• Zhao D, Guo M, Liu B, et al. Frontline science: Tim-3-mediated dysfunctional engulfment of apoptotic cells in SLE . J Leukoc Biol. 2017;102(6):1313–1322.
   PubMed Web of Science ®Google Scholar
• Cheng JH, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263(5154):1759–1762.
   PubMed Web of Science ®Google Scholar
• Jeannin P, Magistrelli G, Aubry JP, et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity. 2000;13(3):303–312.
   PubMed Web of Science ®Google Scholar
• Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol. 2000;164(10):5015–5018.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Srdic-Rajic T, Konjevic G, et al. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239(3):115–122.
   PubMed Web of Science ®Google Scholar
• Mizuta M, Shimizu M, Irabu H, et al. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology. 2020;18:keaa299.
   Google Scholar
• Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102–1110.
   PubMed Web of Science ®Google Scholar
• Geng H, Zhang GM, Li D, et al. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 2006;176(3):1411–1420.
   PubMed Web of Science ®Google Scholar
• Möller-Hackbarth K, Dewitz C, Schweigert O, et al. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem. 2013;288(48):34529–34544.
   PubMed Web of Science ®Google Scholar
• Hansen JA, Hanash SM, Tabellini L, et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(9):1323–1330.
   PubMed Web of Science ®Google Scholar
• Clayton KL, Douglas-Vail MB, Nur-Ur Rahman AK, et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J Virol. 2015;89(7):3723–3736.
   PubMed Web of Science ®Google Scholar
• Li F, Li N, Sang J, et al. Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. Cancer Manage Res. 2018;10:941–951.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index. J Rheumatol. 2000;29(2):288–291.
   Web of Science ®Google Scholar
• Polachek A, Gladman DD, Su J, et al. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res. 2017;69(7):997–1003.
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35.
   PubMed Web of Science ®Google Scholar
• Chiba M, Yanaba K, Hayashi M, et al. Clinical significance of serum soluble T-cell immunoglobulin and mucin domain 3 levels in systemic sclerosis: association with disease severity. J Dermatol. 2017;44(2):194–197.
   PubMed Web of Science ®Google Scholar
• Abu Zaid M, Wu J, Wu C, et al. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017;129(2):162–170.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19(5):685–708.
   PubMed Web of Science ®Google Scholar
• Guo L, Yang XD, Xia Q, et al. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) on kidney tissue from systemic lupus erythematosus (SLE) patients. Clin Exp Med. 2014;14(4):383–388.
   PubMed Web of Science ®Google Scholar
• Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78(3):365–371.
   PubMed Web of Science ®Google Scholar